TearSolutions' lead product, called Lacripep, delivers what no other approved or pipeline drug has been able to: rapid healing of the ocular surface and relief of dry eye symptoms with a best-in-class safety and comfort profile. This was all proven in their first-in-human clinical trial which has led to formal written FDA alignment on our clinical and regulatory path to an unrestricted general Dry Eye indication (which is the same path a dry eye drug called Xiidra took, which sold to Novartis for $5.3B).
The company is raising capital to get Lacripep back into the clinic for the first of two Phase III trials.
Andrew Malloy spent a career on Wall Street and also happens to be part of a 3rd generation family office created because of his...
In a wide ranging discussion, with Lazurite Co-Founder/CEO Eugene Malinskiy, we learn more about the origins of the company, it's current status, and get...
Mr. Barletta is the founder of an advisory firm based in Washington DC called Jones Point. The firm possesses a unique combination of more...
